Identification of Functional Genetic Variants in and Their Association With Risk of Esophageal Cancer
X ZHANG,X MIAO,W TAN,B NING,Z LIU,Y HONG,W SONG,Y GUO,X ZHANG,Y SHEN
DOI: https://doi.org/10.1016/j.gastro.2005.05.003
IF: 29.4
2005-01-01
Gastroenterology
Abstract:Background & Aims: Overexpression of cyclooxygenase-2 (COX-2) is implicated in many steps of cancer development. Single nucleotide polymorphisms (SNPs) in the COX-2 promoter might contribute to differential COX-2 expression and subsequent interindividual variability in susceptibility to cancer. This study sought to identify functional SNPs in the COX-2 promoter and evaluated their effects on the risk of developing esophageal squamous cell carcinoma (ESCC). Methods: Thirty individual DNA samples were sequenced to search for SNPs, and the function of the SNPs was examined by a set of biochemical assays. Genotypes and haplotypes were analyzed in 1026 patients and 1270 controls, and odds ratios and 95% confidence intervals (CIs) were estimated by logistic regression. Results: Three SNPs, −1290A→G, −1195G→A, and −765G→C, were identified; the frequencies of variant alleles were 0.04, 0.51, and 0.02, respectively. The −1195G→A change creates a c-MYB binding site and displays a higher promoter activity. The −1195A-containing haplotypes had significantly increased luciferase expression and COX-2 messenger RNA levels in esophageal tissues compared with the −1195G-containing counterparts. A case-control analysis showed a 1.72-fold (95% CI, 1.35–2.20) and 2.24-fold (95% CI, 1.59–3.16) excess risk of developing ESCC for the −1195AA or −765CC genotype carriers compared with noncarriers. A greater risk of developing ESCC was observed for A−1195-C−765-containing haplotypes compared with G−1195-G−765-containing haplotypes, suggesting an interaction between the −1195G→A and −765G→C polymorphisms in the context of haplotype. Conclusions: These findings indicate that genetic variants in COX-2 may play a role in mediating susceptibility to esophageal cancer. Background & Aims: Overexpression of cyclooxygenase-2 (COX-2) is implicated in many steps of cancer development. Single nucleotide polymorphisms (SNPs) in the COX-2 promoter might contribute to differential COX-2 expression and subsequent interindividual variability in susceptibility to cancer. This study sought to identify functional SNPs in the COX-2 promoter and evaluated their effects on the risk of developing esophageal squamous cell carcinoma (ESCC). Methods: Thirty individual DNA samples were sequenced to search for SNPs, and the function of the SNPs was examined by a set of biochemical assays. Genotypes and haplotypes were analyzed in 1026 patients and 1270 controls, and odds ratios and 95% confidence intervals (CIs) were estimated by logistic regression. Results: Three SNPs, −1290A→G, −1195G→A, and −765G→C, were identified; the frequencies of variant alleles were 0.04, 0.51, and 0.02, respectively. The −1195G→A change creates a c-MYB binding site and displays a higher promoter activity. The −1195A-containing haplotypes had significantly increased luciferase expression and COX-2 messenger RNA levels in esophageal tissues compared with the −1195G-containing counterparts. A case-control analysis showed a 1.72-fold (95% CI, 1.35–2.20) and 2.24-fold (95% CI, 1.59–3.16) excess risk of developing ESCC for the −1195AA or −765CC genotype carriers compared with noncarriers. A greater risk of developing ESCC was observed for A−1195-C−765-containing haplotypes compared with G−1195-G−765-containing haplotypes, suggesting an interaction between the −1195G→A and −765G→C polymorphisms in the context of haplotype. Conclusions: These findings indicate that genetic variants in COX-2 may play a role in mediating susceptibility to esophageal cancer. Cyclooxygenases (COXs, also known as prostaglandin endoperoxide H synthases or prostaglandin G/H synthases) are key enzymes in mediating the conversion of free arachidonic acid into prostaglandin H2, the precursor of molecules such as prostaglandins, prostacyclin, and thromboxanes.1Needleman P. Turk J. Jakschik B.A. Morrison A.R. Lefkowith J.B. Arachidonic acid metabolism.Annu Rev Biochem. 1986; 55: 69-102Crossref PubMed Google Scholar These active products are important regulators of many biologic processes such as inflammation, immune function, cell proliferation, and angiogenesis, which are all relevant to cancer development and progression.2Williams C.S. Mann M. DuBois R.N. The role of cyclooxygenases in inflammation, cancer, and development.Oncogene. 1999; 18: 7908-7916Crossref PubMed Scopus (1245) Google Scholar, 3Fosslien E. Molecular pathology of cyclooxygenase-2 in neoplasias.Ann Clin Lab Sci. 2000; 30: 3-21PubMed Google Scholar, 4Trifan O.C. Hla T. Cyclooxygenase-2 modulates cellular growth and promotes tumorigenesis.J Cell Mol Med. 2003; 7: 207-222Crossref PubMed Scopus (167) Google Scholar, 5Gately S. The contributions of cyclooxygenase-2 to tumor angiogenesis.Cancer Metastasis Rev. 2000; 19: 19-27Crossref PubMed Scopus (340) Google Scholar It has been well known that the COX family consists of 2 isozymes; COX-1 is constitutively expressed in most cell types and involved in the homeostasis of various physiologic functions, whereas COX-2 is an inducible form and its expression can be induced by proinflammatory and mitogenic stimuli such as cytokines and growth factors.6Gasparini G. Longo R. Sarminento R. Morabito A. Inhibitors of cyclooxygenase 2 a new class of anticancer agents?.Lancet Oncol. 2003; 4: 605-615Abstract Full Text Full Text PDF PubMed Scopus (316) Google Scholar Increased expression of COX-2 is observed in many types of cancers, and accumulating evidence indicates that overexpression of COX-2 is associated with many steps of cancer development, including hyperproliferation, transformation, tumor growth, invasion, and metastasis.7Zimmermann K.C. Sarbia M. Weber A.A. Borchard F. Gabbert H.E. Schror K. Cyclooxygenase-2 expression in human esophageal carcinoma.Cancer Res. 1999; 59: 198-201PubMed Google Scholar, 8Shamma A. Yamamoto H. Doki Y. Okami J. Kondo M. Fujiwara Y. Yano M. Inoue M. Matsuura N. Shiozaki H. Monden M. Up-regulation of cyclooxygenase-2 in squamous carcinogenesis of the esophagus.Clin Cancer Res. 2000; 6: 1229-1238PubMed Google Scholar, 9Zhi H. Zhang J. Hu G. Lu J. Wang X. Zhou C. Wu M. Liu Z. The deregulation of arachidonic acid metabolism-related genes in human esophageal squamous cell carcinoma.Int J Cancer. 2003; 106: 327-333Crossref PubMed Scopus (91) Google Scholar, 10Romano M. Claria J. Cyclooxygenase-2 and 5-lipoxygenase converting functions on cell proliferation and tumor angiogenesis implications for cancer therapy.FASEB J. 2003; 17: 1986-1995Crossref PubMed Scopus (215) Google Scholar, 11Buskens C.J. van Rees B.P. Sivula A. Reitsma J.B. Haglund C. Bosma P.J. Offerhaus G.J. van Lanschot J.J. Ristimaki A. Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus.Gastroenterology. 2002; 122: 1800-1807Abstract Full Text Full Text PDF PubMed Scopus (218) Google Scholar, 12Murata H. Kawano S. Tsuji S. Tsuji M. Sawaoka H. Kimura Y. Shiozaki H. Hori M. Cyclooxygenase-2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinoma.Am J Gastroenterol. 1999; 94: 451-455Crossref PubMed Scopus (294) Google ScholarTranscriptional regulation has been shown to be the major mechanism in regulating the expression of COX-2, although posttranscriptional mechanisms such as increased stability of COX-2 mRNA also seem important.6Gasparini G. Longo R. Sarminento R. Morabito A. Inhibitors of cyclooxygenase 2 a new class of anticancer agents?.Lancet Oncol. 2003; 4: 605-615Abstract Full Text Full Text PDF PubMed Scopus (316) Google Scholar Examination of the COX-2 promoter region has identified several key cis-acting regulatory elements, including TATA, PEA3, AP1, nuclear factor interleukin-6, nuclear factor κB, Sp1, adenosine 3′,5′-cyclic monophosphate, c-MYB, and transforming growth factor β response elements, which may play a decisive role in the regulation of COX-2 transcription.13Dixon D.A. Regulation of COX-2 expression in human cancers.Prog Exp Tumor Res. 2003; 37: 52-71Crossref PubMed Scopus (70) Google Scholar Some in vitro experiments have shown that deletion or forced mutations within the consensus sequences of certain cis-acting elements significantly altered gene expression.14Schmedtje Jr, J.F. Ji Y.S. Liu W.L. Dubois R.N. Runge M.S. Hypoxia induces cyclooxygenase-2 via the NF-kappaB p65 transcription factor in human vascular endothelial cells.J Biol Chem. 1997; 272: 601-608Crossref PubMed Scopus (634) Google Scholar, 15Nie M. Pang L. Inoue H. Knox A.J. Transcriptional regulation of cyclooxygenase 2 by bradykinin and interleukin-1beta in human airway smooth muscle cells involvement of different promoter elements, transcription factors, and histone h4 acetylation.Mol Cell Biol. 2003; 23: 9233-9244Crossref PubMed Scopus (104) Google Scholar, 16Xu Q. Ji Y.S. Smedtje J.F. Sp1 increases expression of cyclooxygenase-2 in hypoxic vascular endothelium implication for the mechanisms of aortic aneurysm and heart failure.J Biol Chem. 2000; 275: 24583-24589Crossref PubMed Scopus (103) Google Scholar These findings suggest that naturally occurring sequence variations in the gene might contribute at least in part to differential COX-2 expression and a substantial degree of interindividual variability in susceptibility to cancer and in response to the treatment of patients with COX-2 inhibitors.17Lukiw W.J. Bazan N.G. Cyclooxygenase 2 RNA message abundance, stability, and hypervariability in sporadic Alzheimer neocortex.J Neurosci Res. 1997; 50: 937-945Crossref PubMed Scopus (140) Google Scholar, 18FitzGerald G.A. Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2.N Engl J Med. 2001; 345: 433-442Crossref PubMed Scopus (1402) Google ScholarSeveral single nucleotide polymorphisms (SNPs) in COX-2 have been reported previously, but most of these polymorphisms seem to be functionally insignificant and not associated with susceptibility to cancer,19Humar B. Giovanoli O. Wolf A. Attenhofer M. Bendik I. Meier R. Muller H. Dobbie Z. Germline alterations in the cyclooxygenase-2 gene are not associated with the development of extracolonic manifestations in a large Swiss familial adenomatous polyposis kindred.Int J Cancer. 2000; 87: 812-817Crossref PubMed Scopus (26) Google Scholar, 20Fritsche E. Baek S.J. King L.M. Zeldin D.C. Eling T.E. Bell D.A. Functional characterization of cyclooxygenase-2 polymorphisms.J Pharmacol Exp Ther. 2001; 299: 468-476PubMed Google Scholar, 21Spirio L.N. Dixon D.A. Robertson J. Robertson M. Barrows J. Traer F. Burt R.W. Leppert M.F. White R. Prescott S.M. The inducible prostaglandin biosynthetic enzyme, cyclooxygenase 2, is not mutated in patients with attenuated adenomatous polyposis coli.Cancer Res. 1998; 58: 4909-4912PubMed Google Scholar whereas a coding polymorphism (Val511Ala) has been linked to reduced risk of colorectal neoplasia.22Lin H.J. Lakkides K.M. Keku T.O. Reddy S.T. Louie A.D. Kau I.H. Zhou H. Gim J.S.Y. Ma H.L. Matthies C.F. Dai A. Huang H.-F. Materi A.M. Lin J.H. Frankl H.D. Lee E.R. Hardy S.I. Herschman H.R. Henderson B.E. Kolonel L.N. Le Marchand L. Garavito R.M. Sandler R.S. Haile R.W. Smith W.L. Prostaglandin H synthase 2 variant (Val511Ala) in African Americans may reduce the risk for colorectal neoplasia.Cancer Epidemiol Biomarkers Prev. 2002; 11: 1305-1315PubMed Google Scholar Recently, 2 SNPs (−490C→G and −765G→C) in the COX-2 promoter region (from −1122 to 54 base pairs) have been described in a UK population.23Papafili A. Hill M.R. Brull D.J. McAnulty R.J. Marshall R.P. Humphries S.E. Laurent G.J. Common promoter variant in cyclooxygenase-2 represses gene expression evidence of role in acute-phase inflammatory response.Arterioscler Thromb Vasc Biol. 2002; 22: 1631-1636Crossref PubMed Scopus (321) Google Scholar It has been shown that the −765G→C polymorphism, which appears to disrupt an Sp1-binding site and thus displays a lower promoter activity, is associated with the phenotype of lower level of C-reactive protein in acute inflammatory response to coronary artery bypass graft surgery. In another study,24Panguluri R.C. Long L.O. Chen W. Wang S. Coulibaly A. Ukoli F. Jackson A. Weinrich S. Ahaghotu C. Isaacs W. Kittles R.A. COX-2 gene promoter haplotypes and prostate cancer risk.Carcinogenesis. 2004; 25: 961-966Crossref PubMed Scopus (100) Google Scholar a 1400-base pair DNA upstream of the ATG start site of COX-2 was resequenced and 4 SNPs (−1285A→G [rs3918304], −1265G→A [rs20415], −899G→C [rs20417], and −297C→G [rs5270]) were detected in black and Bini Nigerian patients. However, only 2 of them (−1265G→A and −297C→G) were presented in European Americans and the reported allelic frequencies of these polymorphisms vary greatly among the 3 populations. All of these findings suggest that the genetic variation in COX-2 displays a striking ethnic difference.The diseases in which a role for COX-2 has been shown are usually characterized by varying individual and even ethnic susceptibility, implying the role of genetic factors. The specific function of COX-2 in the formation of prostaglandins and cancer development (vide supra) makes it a strong candidate for several heritable traits such as common cancers. Genetic polymorphisms that alter the level of protein expressed would be anticipated to have a substantial influence on disease activity. In this study, we sought to identify new and functional polymorphisms in the promoter (∼2 kilobases) of the human COX-2 gene and conducted a large case-control study to evaluate the contribution of detected polymorphisms to the risk of developing esophageal squamous cell carcinoma (ESCC), a common cancer in which COX-2 has been shown to play an important role.7Zimmermann K.C. Sarbia M. Weber A.A. Borchard F. Gabbert H.E. Schror K. Cyclooxygenase-2 expression in human esophageal carcinoma.Cancer Res. 1999; 59: 198-201PubMed Google Scholar, 8Shamma A. Yamamoto H. Doki Y. Okami J. Kondo M. Fujiwara Y. Yano M. Inoue M. Matsuura N. Shiozaki H. Monden M. Up-regulation of cyclooxygenase-2 in squamous carcinogenesis of the esophagus.Clin Cancer Res. 2000; 6: 1229-1238PubMed Google Scholar, 9Zhi H. Zhang J. Hu G. Lu J. Wang X. Zhou C. Wu M. Liu Z. The deregulation of arachidonic acid metabolism-related genes in human esophageal squamous cell carcinoma.Int J Cancer. 2003; 106: 327-333Crossref PubMed Scopus (91) Google Scholar, 11Buskens C.J. van Rees B.P. Sivula A. Reitsma J.B. Haglund C. Bosma P.J. Offerhaus G.J. van Lanschot J.J. Ristimaki A. Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus.Gastroenterology. 2002; 122: 1800-1807Abstract Full Text Full Text PDF PubMed Scopus (218) Google ScholarSubjects and MethodsSNP ScreeningThirty DNA samples deriving from blood of randomly selected healthy subjects (all were Han Chinese) were used to search for SNPs within the promoter region of COX-2 (2310 base pairs). These samples included 60 chromosomes, providing at least a 95% confidence level to detect alleles with frequencies >5%. In reference to the human COX-2 gene promoter sequence (GenBank accession no. AY382629 ), 5 sets of polymerase chain reaction (PCR) primers (provided on request) were designed for SNP screening. The 5 COX-2 promoter fragments from each subject were amplified, and SNPs were identified by directly sequencing the PCR products with ABI PRISM Dye Terminator Sequencing Kits (Applied Biosystems, Foster City, CA) and loading the samples onto an ABI 3700 sequencer. Finally, we used the Mutation Explorer program (Todaysoft Inc, Beijing, China) to identify SNP candidates that were then confirmed by 2 independent observers. We further confirmed these SNP positions and individual genotypes by reamplifying and resequencing the SNP site from the opposite strand.Subjects for the Case-Control StudyThis study included 1026 patients with ESCC and 1270 cancer-free controls. All subjects were unrelated ethnic Han Chinese. Patients were consecutively recruited between July 1999 and July 2003 at the Cancer Hospital of the Chinese Academy of Medical Sciences in Beijing. All patients with histopathologically confirmed ESCC were enrolled, and there was no sex and age restriction. The response rate for patients was 92%. The exclusion criteria included previous cancer and previous chemotherapy or radiotherapy. Among 1026 patients, 588 were participants in a molecular epidemiologic study of esophageal cancer as described previously.25Sun T. Miao X. Zhang X. Tan W. Xing P. Lin D. Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma.J Natl Cancer Inst. 2004; 96: 1030-1036Crossref PubMed Scopus (177) Google Scholar Controls were cancer-free individuals randomly selected from a community cancer screening program for early detection of cancer conducted in the same regions during the same period the patients were recruited. The response rate for controls was 89%. The characteristics of most controls (n = 648) were described previously.25Sun T. Miao X. Zhang X. Tan W. Xing P. Lin D. Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma.J Natl Cancer Inst. 2004; 96: 1030-1036Crossref PubMed Scopus (177) Google Scholar The selection criteria for the controls included no individual history of cancer and frequency matched to case patients based on sex and age (±5 years). In this study, we also selected 622 more controls from the same database frequency matched to case patients based on age and sex as described previously, for a total of 1270 controls. At recruitment, informed consent was obtained from each subject and personal data from each participant regarding demographic characteristics such as sex and age and related risk factors including tobacco smoking were collected via questionnaire. This study was approved by the institutional review board of the Chinese Academy of Medical Sciences Cancer Institute.COX-2 GenotypingGenomic DNA was extracted from peripheral blood lymphocytes of all controls and most patients. Twenty-eight percent of DNA samples from patients were isolated from surgically removed normal tissues adjacent to the tumors. Genotypes were determined by PCR-based restriction fragment length polymorphism. The PCR primer pairs used to amplify the COX-2 promoter region containing −765G→C, −1195G→A, and −1290A→G sites were 765F5′-tattatgaggagaatttacctttcgc-3′/765R5′-gctaagttgctttcaacagaagaaat-3′, 1195F5′-ccctgagcactacccatgat-3′/1195R5′-gcccttcataggagatactgg-3′, and 1290F5′-caggttttatgctgtcattttcc-3′/1290R5′-tagtgctcagggaggagcat-3′. PCR was performed at a 25-μL reaction mixture containing 100 ng of DNA, 0.1 μmol/L of each primer, 0.2 mmol/L of deoxynucleoside triphosphate, 1.0 U of Taq DNA polymerase (Promega, Madison, WI), and 1× reaction buffer. The concentration of MgCl2 was 3.0 mmol/L for the −765G→C site and 1.5 mmol/L for both the −1195G→A site and the −1290A→G sites. The PCR profile consisted of an initial melting step of 2 minutes at 95°C, followed by 35 cycles of 30 seconds at 94°C, 30 seconds at 62°C (for the −765G→C site) or 60°C (for both the −1195G→A and the −1290A→G sites), 45 seconds at 72°C, and a final elongation step of 7 minutes at 72°C. Restriction enzymes HhaI, PvuII, or RsaI (New England Biolabs, Beverly, MA) was used to distinguish the −765G→C, −1195G→A, or −1290A→G genotypes, respectively. Genotyping was performed without knowledge of the case/control status of the subjects. A 10% random sample of cases and controls was tested twice by different persons, and all results were 100% concordant.Haplotype Construction and Statistical AnalysisUnconditional logistic regression was used to assess the association between genotypes and the risk of ESCC using SAS software (version 6.12; SAS Institute, Inc, Cary, NC). Odds ratios (ORs) were all adjusted for age, sex, and smoking where appropriate. A P value of